Researchers have identified mutations in a set of proteins that predispose their carriers to preeclampsia, a complication that shows up in between 5 percent and 10 percent of pregnancies. Their work ...

- Proprietary tissue-targeted complement platform and best-in-class IL-7R antibody technology to treat patients with severe autoimmune and inflammatory disease; clinical trials begin in 2020 ...